

Patient ID SA00162649	Patient Name TESTINGRNV, RAVMP	Birth Date 1990-02-15	Sex F	Age 33
Order Number SA00162649	Client Order Number SA00162649	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 05 Oct 2023 06:00		

Ravulizumab Monitoring Panel, S

Ravulizumab Interpretation, S

Ravulizumab Interpretation

1 SDL

Alternative pathway of complement function is undetectable. Ravulizumab concentration is therapeutic, suggesting complete C5 blockage.

Ravulizumab Complement Blockage, S

1 SDL

 **<10 %of norm**
Low

Reference Value
≥46

ADDITIONAL INFORMATION

Monitoring ravulizumab complement blockage is performed by measurement of the alternative complement pathway through AH50 testing.

Ravulizumab, S

1 SDL

177.0 mcg/mL

REFERENCE VALUE

Lower limit of quantitation = 5.0 mcg/mL

>175 mcg/mL therapeutic concentration for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)

Received: 05 Oct 2023 07:39

Reported: 05 Oct 2023 15:38

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592